This study was designed to elucidate the therapeutic potentialof JNK inhibition in the treatment of lung cancer cells with cisplatin.Using the lung adenocarcinoma cell line A549 as a model, along withother patient-derived primary lung cancer cell lines, we demonstrateda cisplatin concentration-dependent, mutually/intrinsically antagonisticrole of JNK in regulating cancer cell fate. This evidence concerns the gene MAPK8 and lung carcinoma.